Specifically, low constitutive NER capacity and low levels of XPA, XPF and ERCC1 (NER proteins) have been reported in cisplatin-hypersensitive testicular cancer cells compared to other tumor types resistant to cisplatin [12]. The gene discussed is ERCC4; the disease is testicular cancer.